Intranasal vaccines may outperform COVID-19 shots


SARS-CoV-2 inhabits the nose, windpipe and lungs, and some researchers are working on antiviral drugs and vaccines that are delivered nasally to induce both mucosal and systemic immunity. SARS-CoV-2 was detected in the nasal passages of lab animals immunized with systemic vaccines but not among those that got intranasal vaccines, but problems with intranasal influenza vaccines have made it harder to develop similar vaccines for other viruses.

Full story:

FBR SmartBrief

Biomedical research news.

FBR SmartBrief is a FREE, weekly e-mail newsletter. By providing the latest need-to-know industry news and information, FBR SmartBrief saves you time and keeps you smart.